The effect of metformin on serum visfatin in relation to polycystic ovarian syndrome, obesity and insulin resistance

Kalan, M.J.; Fogle, R.H.; Baker, Marsha; Allen, R.B.; Sokol, Ronald J.; Stanczyk, Frank Z.

doi:10.1016/j.fertnstert.2007.07.261

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melbine, a kind of biguanide, can directly act on the body to promote the utilization of glucose in adipose tissues or muscle, decrease the output of hepatic glucose, enhance the intake, transportation and utilization of glucose in peripheral tissues, inhibit the degradation of fat, increase the oxidization of glucose, absorption of glucose in the gastrointestinal tract and block the entrance of glucose into the peripheral blood, thereby decreasing the level of plasma glucose (22,23). Research has shown that after administration of melbine, T2DM patients had a lowered level of plasma glucose, and 12 weeks later, FPG was decreased to 3.0 to 5.0 mmol/L, PPG to 7.1 to 8.0 mmol/L and HbA1c to 1.5% to 2.0% (24,25). It has been reported that the application of melbine for T2DM patients can effectively prevent the occurrence of complications in micro-or macro-vessels, thus protecting the cardiovascular system and decreasing the incidence of cardiovascular diseases (26).…”

Section: Discussionmentioning

confidence: 99%

Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone

Sun

Xie

2020

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study was founded for the purpose investigate the differences in effects of combined medication of pioglitazone and melbine and single-use of pioglitazone on the levels of hba1c, blood fat and insulin sensitivity of elder patients with type II diabetes mellitus (T2DM), to provide clinical reference and guidance for the treatment of T2DM in elder patients. For this purpose, we selected a total of 120 elder patients with T2DM who visited the clinic or were admitted to this hospital between July 2016 and July 2017 and divided them into the observation group and the control group (n=60 for each group). For the control group, they only took pioglitazone for treatment, while those in the observation additionally took melbine for treatment. Then, we observed the levels of FPG, 2hPG, HbA1c, blood fat, FINS, 2hINS and HOMA-IR. Results showed that after treatment, significant decreases were seen in levels of FPG, 2hPG and HbA1c in patients of two groups compared to the levels before treatment, and the levels in the observation group decreased more evidently than those in the control group (p<0.05); besides, the levels of total glyceride, total cholesterol and LDL-C were all significantly lower than those before treatment, with an elevated HDL-C, and those levels of TG, TC and LDL-C in the observation group were significantly lower than those in the control group; the level of HDL-C was higher than the control group (p<0.05). Similar decreases were identified in the levels of FINS, 2hFINS and HOMA-IR after treatment (p<0.05), and the levels in the observation group were also significantly lower than those in the control group (p<0.05). In the observation group, the incidence rate of adverse reactions was 10% (6/60), while in the control group was 8.33% (5/60), but the difference between the two groups showed no statistical significance (p>0.05). It is concluded that combined medication of pioglitazone and melbine can effectively reduce the levels of plasma glucose, blood fat and the HOMA-IR, with an elevated sensitivity to insulin, but no severe adverse reactions, manifesting a promising safety in long-term administration. It is worthy of being promoted in clinical practice.

show abstract